Haleos Labs Q3 FY26: Net Profit ₹540 Cr Standalone, ₹664 Cr Consolidated
Haleos Labs reported Q3 FY26 standalone net profit of ₹5.41 crore (down from ₹6.23 crore YoY) and consolidated net profit of ₹6.65 crore (up from ₹4.85 crore YoY). The company will issue a Corporate Guarantee of ₹20 crore for its subsidiary, Mahi Drugs, subject to shareholder approval via postal ballot.
The corporate guarantee for ₹20 crore represents a significant contingent liability, although it is for a material subsidiary. The increase in consolidated profit is also a positive factor.
The consolidated net profit shows an increase year-on-year, and the company is taking steps to support its subsidiary's financing needs, which is a positive development.
Haleos Labs Limited announced its un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on February 11, 2026.
For the quarter ended December 31, 2025, the standalone net profit was ₹540.68 Lakhs (₹5.41 crore), a decrease from ₹622.75 Lakhs (₹6.23 crore) in the same quarter last year. Revenue from operations stood at ₹8,071.91 Lakhs (₹80.72 crore). For the nine months ended December 31, 2025, the standalone net profit was ₹1,554.21 Lakhs (₹15.54 crore), down from ₹1,869.57 Lakhs (₹18.70 crore) in the prior year period, with revenue from operations at ₹23,760.54 Lakhs (₹237.61 crore).
On a consolidated basis, the net profit for the quarter ended December 31, 2025, was ₹664.89 Lakhs (₹6.65 crore), an increase from ₹485.31 Lakhs (₹4.85 crore) in the corresponding quarter of the previous year. Consolidated revenue from operations was ₹9,478.31 Lakhs (₹94.78 crore). For the nine months ended December 31, 2025, the consolidated net profit was ₹1,745.63 Lakhs (₹17.46 crore), up from ₹1,524.96 Lakhs (₹15.25 crore) in the previous year, with revenue from operations at ₹25,865.54 Lakhs (₹258.66 crore).
The company also approved the issue of a Corporate Guarantee to RBL Bank for ₹20 Crore on behalf of its subsidiary, Mahi Drugs, for availing External Commercial Borrowings. This issuance is subject to shareholder approval, and the company will conduct a postal ballot for this purpose. Additionally, the Board reviewed and approved the outcome of the separate meeting of Independent Directors, who assessed their performance and the flow of information from management as satisfactory.
What to do with a filing like this
HALEOS LABS LIMITED filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by HALEOS LABS LIMITED. Read the original for the full detail.